September opens with eleven live FDA clocks spanning label expansions, resubmissions, ultra-rare disease filings and a manufacturing-driven binary.
The sequence starts with an unresolved Sunday action date, moves through Advicenne and Telix in the first half of the month, then compresses sharply: five decisions are scheduled between September 26 and September 30.
Last week reinforced why the decision headline is only the first read. Ziihera won two first-line regimens with different HER2 populations. BIXLENVO’s label carries a component-resistance boundary. MIMRYLO was approved specifically for erythrocytosis in adults with polycythemia vera.
PharmaEssentia’s BESREMi date fell on Sunday. As of writing, neither FDA nor the sponsor has announced an outcome. The event remains live pending a public disclosure; it is not a presumed approval or CRL.
| DATE | SPONSOR | EVENT | SETUP | RISK | PoA |
| Sun Aug 30 | PharmaEssentia | BESREMi essential thrombocythemia | Standard sBLA | Label / benefit-risk | 87% |
| Thu Sep 3 | Advicenne | Sibnayal distal RTA | 505(b)(2) NDA | Bridge / CMC / label | 78% |
| Fri Sep 11 | Telix | TLX101-Px (Pixclara) glioma PET | Resubmitted NDA FT / ODD | Evidence / execution | 75% |
| Sat Sep 19 | RARE | UX111 Sanfilippo A | Resubmitted BLA accelerated approval | CMC / facility | 79% |
| Mon Sep 21 | MRK | WINREVAIR PAH label update | sBLA / HYPERION | Label / execution | 96% |
| Tue Sep 22 | IONS | zilganersen Alexander disease | Priority NDA | Endpoint / age | 84% |
| Sat Sep 26 | MIRM / INCY | zilurgisertib FOP, ages 12+ | Priority NDA | Dataset / label | 78% |
| Mon Sep 28 | Egetis | Emcitate MCT8 deficiency | Priority NDA | Evidence / label | 83% |
| Mon Sep 28 | BFRI | Ameluz PDT superficial BCC | sNDA / device | Label / device | 85% |
| Wed Sep 30 | BMY | CAMZYOS adolescent oHCM | Priority sNDA | Pediatric label | 91% |
| Wed Sep 30 | SRRK | apitegromab spinal muscular atrophy | BLA resubmission | Fill-finish / CMC | 74% |
Board dates reflect sponsor and FDA disclosures. PoAs are PDUFA Pulse editorial estimates rounded to whole numbers.
FDA approved two first-line Ziihera regimens for HER2-positive advanced gastroesophageal adenocarcinoma. The triplet covers HER2 IHC 3+ or IHC 2+/ISH+ tumors without a PD-L1 restriction; the doublet is limited to IHC 3+ disease.
FDA approved bictegravir/lenacapavir for virologically suppressed adults on a stable regimen, with no known or suspected resistance to the individual components.
FDA approved LISRAYA for adults with dermatomyositis on August 27 and MIMRYLO for erythrocytosis in adults with polycythemia vera on August 28.
The BLA already included a second U.S. fill-finish facility. Scholar Rock removed Catalent Indiana after its OAI classification; FDA’s review of the second facility continues. In Europe, the company withdrew the MAA and plans to resubmit without Catalent.
MIRM, Egetis, BFRI, BMY and SRRK create five scheduled decisions in five days, spanning four distinct regulatory failure modes.
Weekend-disclosure risk. PharmaEssentia remains unresolved as of writing; RARE’s September 19 and MIRM’s September 26 dates carry the same disclosure-timing problem.
Evidence bridging and resubmission risk. Advicenne depends on a U.S. bridge from European evidence. Telix returns over diagnostic evidence; UX111 returns over CMC and facility remediation.
Small-population evidence risk. Ionis, Mirum/Incyte and Egetis require FDA to read endpoint validity, population coverage and benefit-risk from limited data.
| SRRK$SRRK · apitegromab | SEP 30 · 74% |
The clinical story is not the principal uncertainty. The commercial manufacturing path is.
The BLA already included a second U.S. fill-finish facility whose FDA review was underway. Scholar Rock removed Catalent Indiana after its OAI classification and says it has commercial supply from the second site.
If CRL: Facility review, comparability or launch-readiness documentation—not a reversal on clinical efficacy.
| IONS$IONS · zilganersen | SEP 22 · 84% |
Ionis has a randomized, controlled pivotal dataset in a disease with no approved disease-modifying therapy.
In the 53-person Phase 1–3 study, the 50 mg dose stabilized gait speed versus control in participants five years and older at Week 61, with a 33.3% least-squares mean difference and p=0.041. The younger two-to-four-year-old cohort used a different GMFM-88 endpoint; its favorable analysis was nominal and not controlled for multiplicity.
Read-through: A positive binary can still leave the lower age boundary and label language as the material question.
A BLA can be strong on clinical data and still depend on a facility decision. The Catalent OAI does not say apitegromab failed in patients; it says one path in the commercial package created an FDA review problem.
The question is whether the existing second-facility package closes the remaining CMC review within the existing window—not whether efficacy can compensate for an unready manufacturing path.
| PharmaEssentia | Label breadth, benefit-risk or sBLA execution? |
| Advicenne | European-data bridge, CMC or U.S. label? |
| Telix | Diagnostic-evidence response, label or manufacturing? |
| RARE / UX111 | CMC or facility remediation incomplete? |
| MRK | Unexpected label, safety or application-execution issue? |
| IONS | Small pivotal dataset or age-boundary evidence insufficiently robust? |
| MIRM / INCY | Phase 2 evidence, benefit-risk or 12-and-older label scope? |
| Egetis | Ultra-rare evidence package or proposed indication? |
| BFRI | Drug-device label, manufacturing or sBCC evidence? |
| BMY | Pediatric safety monitoring or label mechanics? |
| SRRK | Second-facility review, comparability or launch documentation? |
All four August approvals are resolved board events. Read the population definitions and resistance/indication boundaries before treating the headlines as identical outcomes.
Immediate status: PharmaEssentia remains unresolved after its Sunday target date as of writing. Advicenne is the first confirmed September clock.
Cleanest setup: MRK. This is an existing-product label update, not a first approval.
Highest-drama setup: SRRK. The European withdrawal shows the Catalent issue has consequences, even though the U.S. file retains its September 30 clock.
Late-month compression: MIRM → Egetis/BFRI → BMY/SRRK creates five decisions in five days, with four different regulatory failure modes.
Informational only · Not investment advice · Biotech carries risk of total loss.